A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association with Molecular Target Expression

This publication has 25 references indexed in Scilit:

• Phase II Study of Pemetrexed in Patients Pretreated with an Anthracycline, a Taxane, and Capecitabine for Advanced Breast Cancer
  Clinical Breast Cancer, 2005
• Can Patients' Likelihood of Benefiting from Primary Chemotherapy for Breast Cancer Be Predicted Before Commencement of Treatment?
  Breast Cancer Research and Treatment, 2004
• Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
  Journal of Clinical Oncology, 2004
• Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
  Journal of Clinical Oncology, 2004
• Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
  Journal of Clinical Oncology, 2003
• Loss of folylpoly‐γ‐glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation‐dependent novel antifolates in multiple human leukemia sublines
  International Journal of Cancer, 2002
• Assessing TP53 status in human tumours to evaluate clinical outcome
  Nature Reviews Cancer, 2001
• Resistance to Tomudex (ZD1694): Multifactorial in human breast and colon carcinoma cell lines
  Biochemical Pharmacology, 1996
• Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil
  Biochemical Pharmacology, 1995
• Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexate
  Biochemistry, 1983